Acceptability of a Dapivirine/Placebo Gel Administered Rectally to HIV-1 Seronegative Adults (MTN-026)

Academic Article

Abstract

  • This study describes the acceptability of a rectal microbicide gel formulation using dapivirine (DPV) among men and women from two countries (United States and Thailand) participating in the Microbicide Trials Network-026 trial. We evaluated participants’ acceptability of a rectal DPV/placebo gel as part of a Phase I trial (N = 26; 18 male, 8 female). Participants reported favorable acceptability of the study gel, with most participants reporting that they liked the gel the same (n = 14; 53.8%) or more (n = 11; 42.4%) than when they started the trial. Over half of participants noted that they would prefer the gel over condoms (n = 13; 50%) or that they liked condoms and the gel equally (n = 8; 30.8%). Side effects across products included leakage (n = 8; 30.8%), diarrhea (n = 4; 15.4%), or soiling (n = 1; 3.8%). The high acceptability of a rectal gel underscores its promise as a short-acting biomedical prevention, warranting future research for HIV prevention. Trial Registration: NCT03239483.
  • Authors

    Published In

  • AIDS and Behavior  Journal
  • Digital Object Identifier (doi)

    Author List

  • Bauermeister JA; Tingler RC; Dominguez C; Dunne EF; Hoesley C; Ho K; Johnson S; Lucas J; Macagna N; Brown E
  • Start Page

  • 1333
  • End Page

  • 1346
  • Volume

  • 26
  • Issue

  • 5